Mobile

Safety and efficacy of MPDL3280A (anti-PDL1 antibody) compared to gemcitabine + platinum-based chemotherapy in previously untreated patients with metastatic, squamous, PD-L1-selected, non-small cell l...

Update Il y a 5 ans
Reference: EUCTR2014-003106-33

Safety and efficacy of MPDL3280A (anti-PDL1 antibody) compared to gemcitabine + platinum-based chemotherapy in previously untreated patients with metastatic, squamous, PD-L1-selected, non-small cell lung cancer

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective for this study is to evaluate the efficacy of MPDL3280A compared with carboplatin or cisplatin + gemcitabine in chemotherapy-naive patients with Stage IV squamous NSCLC, as measured by investigator-assessed PFS according to RECIST v1.1

Inclusion criteria

  • Previously untreated Stage IV, Squamous, Non-Small Cell Lung Cancer

Links